Pressure BioSciences to Present at Upcoming Life
Sciences Investor Forum
Company Invites Individual and Institutional Investors, as well as
Advisors and Analysts, to Attend Live, Interactive
Presentations on Thursday, December 17, 2020
South
Easton, MA -- December 15, 2020 -- InvestorsHub NewsWire
-- Pressure BioSciences, Inc. (OTCQB:
PBIO) ("PBI" and the "Company") today announced that the
Company will participate in the Life Sciences Investor Forum
("LSIF") on Thursday December 17, 2020. LSIF is a live,
interactive investor event held quarterly for public and private
companies, investors, and industry professionals from around the
world. This day-long, virtual event will showcase live company
presentations and interactive discussions focused on the life
sciences industry. PBI's President and CEO, Mr. Richard T.
Schumacher, is scheduled to
present at 11am
ET.
Pre-registration is
recommended, to expediate participation and to receive event
updates. If attendees are
unable to join the event live, an archived webcast will be made
available after the event. Instructions on how to access this
archive will be available at
www.lifesciencesinvestorforum.com and on PBI's
website
www.pressurebiosciences.com.
DATE: Thursday,
December 17, 2020
TIME:
11am ET
LINK:
https://bit.ly/3mPSVkO
Recent
Company Highlights
-
Pressure
Cycling Technology ("PCT") Platform
-
Entered
into a
worldwide, co-marketing alliance with Leica Microsystems (a Danaher
company), integrating PBI's
PCT platform with
Leica's
Laser
Microdissection
platform. This
combination
of platforms
results in a tumor processing workflow that offers
the
potential to accelerate and
enhance cancer
R&D
-
PBI
and privately
held RedShiftBio
demonstrated the potential of combining proprietary technologies to
enable a new tool for the development and production of
biotherapeutics
-
Multiple
presentations and publications worldwide highlighted the advantages
of the PCT platform in the preparation of samples to study diseases
and disorders, including infectious diseases (e.g.,
COVID-19)
-
BaroFold
Technology
("BaroFold") Platform
-
Working
with two biopharma
companies to determine if the
patented
BaroFold platform could significantly impact and improve the
quality of their early-stage protein
therapeutics
-
Discussions
underway
with
potential CRO and CMO partners for the expansion of our BaroFold
services
-
Ultra Shear Technology ("UST")
Platform
-
Awarded
first U.S. patent for novel,
proprietary UST
Platform
-
Planned
launch
of
UST-based
BaroShear
K45 Nanoemulsification System for
mid-2021
-
UST
could
revolutionize
processing of immiscible liquids (e.g.,
oils
in water) into
water-soluble,
long-term stable, highly absorbable, innately bioavailable
nanoemulsions
About
Life
Sciences Investor Forum
Life
Sciences Investor Forum is the leading proprietary investor
conference series that provides an interactive forum for
life
sciences companies to
meet with and present directly to investors.
A
real-time solution for investor engagement, Life Sciences Investor
Forum is powered by Intrado
Digital
Media and specifically designed for more efficient investor access.
Replicating the look and feel of on-site investor conferences, Life
Sciences Investor Forum combines leading-edge conferencing and
investor communications capabilities with a comprehensive global
investor audience network.
About
Pressure
BioSciences,
Inc.
Pressure
BioSciences,
Inc.
(OTCQB:
PBIO)
is
a
leader
in
the
development
and
sale
of
innovative,
broadly
enabling,
pressure-based
solutions
for
the
worldwide
life
sciences
and
other
industries.
Our
products
are
based
on
the
unique
properties
of
both
constant
(i.e.,
static)
and
alternating
(i.e.,
pressure
cycling
technology,
or
PCT)
hydrostatic
pressure.
PCT
is a
patented
enabling
technology
platform
that
uses
alternating
cycles
of hydrostatic
pressure
between
ambient
and
ultra-high
levels
to safely
and
reproducibly
control
bio-molecular
interactions
(e.g.,
cell
lysis,
biomolecule
extraction).
Our
primary
focus
is
the
development
of PCT-based
products
for
biomarker
and
target
discovery,
drug
design
and
development,
biotherapeutics
characterization
and
quality
control,
soil
&
plant
biology,
forensics,
and
counter-bioterror
applications.
Additionally,
major
new
market
opportunities
have
emerged
in
the
use
of
our
pressure-based
technologies
in
the
following
areas:
(1)
the
use
of our
recently
acquired,
patented
technology
from
BaroFold,
Inc.
(the
"BaroFold"
technology)
to
allow
entry
into
the
bio-pharma
contract
services
sector,
and
(2)
the
use
of our
recently-patented,
scalable,
high-efficiency,
pressure-based
Ultra
Shear
Technology
("UST")
platform
to
(i)
create
stable
nanoemulsions
of otherwise
immiscible
fluids
(e.g.,
oils
and
water)
and
to
(ii)
prepare
higher
quality,
homogenized,
extended
shelf-life
or room
temperature
stable
low-acid
liquid
foods
that
cannot
be
effectively
preserved
using
existing
non-thermal
technologies.
Forward
Looking
Statements
This
press
release
contains
forward-looking
statements.
These
statements
relate
to future
events
or
our
future
financial
performance
and
involve
known
and
unknown
risks,
uncertainties
and
other
factors
that
may
cause
our
or
our
industry's
actual
results,
levels
of
activity,
performance
or
achievements
to
be
materially
different
from
any
future
results,
levels
of activity,
performance
or
achievements
expressed,
implied
or inferred
by these
forward-looking
statements.
In some
cases,
you can
identify
forward-looking
statements
by
terminology
such
as
"may,"
"will,"
"should,"
"could,"
"would,"
"expects,"
"plans,"
"intends,"
"anticipates,"
"believes,"
estimates,"
"predicts,"
"projects,"
"potential"
or "continue"
or the
negative
of
such
terms
and
other
comparable
terminology.
These
statements
are
only
predictions
based
on
our
current
expectations
and projections
about
future
events.
You
should
not
place
undue
reliance
on
these
statements.
In evaluating
these
statements,
you
should
specifically
consider
various
factors.
Actual
events
or results
may
differ
materially.
These
and
other
factors
may cause
our actual
results
to
differ
materially
from
any
forward-looking
statement.
These
risks,
uncertainties,
and
other
factors
include,
but
are
not
limited
to,
the
risks
and
uncertainties
discussed
under
the
heading
"Risk
Factors"
in
the
Company's
Annual
Report
on
Form
10-K
for
the
year
ended
December
31,
2019,
and
other
reports
filed
by
the
Company
from
time
to
time
with
the
SEC.
The
Company
undertakes
no
obligation
to
update
any
of the
information
included
in this
release,
except
as
otherwise
required
by law.
For more information
about PBI and this press release, please click on the following
website link:
http://www.pressurebiosciences.com
Please visit us on
Facebook, LinkedIn, and Twitter.
Pressure Biosciences (CE) (USOTC:PBIO)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025
Pressure Biosciences (CE) (USOTC:PBIO)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025
